Siloton Secures £313k Seed Funding to Advance Chip-Based Eye Imaging Technology

London-registered and Bristol-headquartered health technology startup Siloton Limited has secured £313.1k in a new seed funding round. The allotment, dated 27 February 2026 and filed on 11 March 2026, brings the company to an estimated post-money valuation of £7.3m.

Founded in April 2020 by Euan Allen and currently led by Chief Executive Officer Dr Alasdair Price, Siloton develops portable, chip-based optical coherence tomography (OCT) devices designed for at-home and community-based monitoring of retinal diseases. The company aims to address the growing burden of conditions such as age-related macular degeneration, glaucoma, and diabetic macular oedema. According to the Macular Society, age-related macular degeneration is the leading cause of sight loss in the UK, with approximately 39,800 people developing the wet form of the condition each year.

Traditionally, OCT systems are bulky, expensive, and fragile, requiring patients to make frequent hospital visits for monitoring. Siloton solves this problem by compressing these complex optical components onto a single photonic integrated circuit smaller than a £1 coin. This miniaturised technology, known as Akepa, allows patients to monitor their eye health from home. The company estimates this innovation could eventually save the NHS over £1bn annually by reducing outpatient appointments. The technology has already garnered support from major institutions, including Moorfields Eye Hospital and the Macular Society, and has attracted interest from the European Space Agency for monitoring eye problems in astronauts.

Siloton currently operates with a team of between five and ten employees, according to recent corporate accounts and professional network data. Revenue and profit figures remain undisclosed as the company is still in its pre-commercial research and development phase, focusing on bringing its technology to market for researchers and clinicians.

This latest £313.1k seed injection builds upon a series of recent funding successes for the company. In October 2024, Siloton raised £860k in a seed round backed by the Evenlode Foundation, South East Angels, the Francis Crick Institute, and an Innovate UK Biomedical Catalyst grant. South East Angels subsequently led a further £1m seed investment announced in late 2025. While specific investors for this March 2026 allotment have not been formally disclosed in the latest filing, the round demonstrates continued capital support as the company moves closer to commercialising its quantum photonic chip technology. The £7.3m valuation reflects steady growth as Siloton transitions from pure research and development into product deployment.

The funding arrives amid a robust period for the UK health technology and medical device sectors. Data from the end of 2024 indicated that UK health tech startups reached a combined valuation of £32bn, having collectively raised £27.4bn in historical funding. Furthermore, the UK medical technology market was projected to reach £15.7bn by the end of 2025. Siloton's focus on hardware miniaturisation and remote patient monitoring aligns with broader NHS and government initiatives, such as the £30m HealthTech Adoption Acceleration Fund, which seek to integrate cost-saving digital health tools and alleviate pressure on traditional healthcare infrastructure.